Injectable HIV Treatment Shows Superior Viral Control Over Daily Pills

Research findings reveal a marked advantage for long-acting injectable HIV treatments compared to conventional daily pill regimens in maintaining viral suppression among young patients. The study tracked adolescents over a 96-week period, revealing that only 1 per cent of those receiving injectable treatment experienced confirmed viral rebound, substantially lower than the 6 per cent observed in the daily pill group.

These results suggest that injectable antiretroviral formulations could transform HIV management strategies, particularly for adolescent populations who may face adherence challenges with daily medication schedules. The lower incidence of viral rebound indicates improved sustained viral suppression, which is critical for preventing disease progression and reducing transmission risk.

The findings published in The Lancet add to growing evidence supporting long-acting injectable therapies as viable alternatives to oral antiretroviral regimens. For India, where HIV treatment programs serve millions of patients, these results offer potential implications for treatment protocols and patient management strategies moving forward.

Experts suggest that injectable options could enhance treatment outcomes by reducing the burden of daily medication adherence, a persistent challenge in HIV care across the region. The data underscores the importance of expanding access to diverse antiretroviral delivery methods to meet varying patient needs and circumstances.